EP0188351A2 — Chemical compounds
Assigned to Smith Kline and French Laboratories Ltd · Expires 1986-07-23 · 40y expired
What this patent protects
Compounds of structure (I) <CHEM> in which, R<1> is -CH2CR<2>R<3>NR<4>R<5> or YCOR<6>; R<2> is hydrogen or C1-4alkyl; R<3> is hydrogen or -COR<6>; R<4> is hydrogen or C1-4alkyl; R<5> is hydrogen, C1-4alkyl …
USPTO Abstract
Compounds of structure (I) <CHEM> in which, R<1> is -CH2CR<2>R<3>NR<4>R<5> or YCOR<6>; R<2> is hydrogen or C1-4alkyl; R<3> is hydrogen or -COR<6>; R<4> is hydrogen or C1-4alkyl; R<5> is hydrogen, C1-4alkyl or C1-4alkanoyl; R<6> is hydroxy, C1-4alkoxy, or -NR<4>R<5>; Y is a bond or C1-4alkylene; R<7> and R<8> are the same or different and are each hydrogen, halogen, C1-4alkyl, nitro or amino; X is oxygen, sulphur, or CH2; R<9> is hydroxy or a bioprecursor theri20; R<1><0> is hydrogen or C1-4alkyl; and Ar is 4-hydroxyphenyl, 5-hydroxy-2-pyridyl, 6-oxo-3(1H)-pyridyl or a 6-oxo-3(1H)-pyridazinyl group and pharmaceutically acceptable salts thereof, processes for their preparation, intermediates useful in their preparation, pharmaceutical compositions containing them and their use in therapy as antihyperlipidaemic agents.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.